News
ROCTOOL: ENRX and ROCTOOL combine their expertise to electrify molds on a global scale
Median Technologies: Financial Communication Schedule for the Second Half of 2023
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT), announces the publication date for its 2023 half year results and its Q3, 2023 business performance:
Publicati
BILENDI: H1 2023 revenues: €29.6 million +2.0% at constant exchange rates
Portzamparc Groupe BNP Paribas Initiates the Coverage of Median Technologies with a “Strong Buy” Recommendation
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) announces today the publication of an initiation report by Portzamparc Groupe BNP Paribas, a French leading group covering
ROCTOOL: Confirmed acceleration in sales growth in first-half 2023: +24%
Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Median Technologies to Host Two Webcasts and Provide a Company Update on July 20, 2023
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on July 20, 2023 during
Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD
Regulatory News:
Median Technologies (ALMDT) announces today that the Company has officially commenced operations with all investigator sites participating in the pivotal validation plan for its
Median Technologies Reports Its Business Activity for the First Half of 2023 and Announces the First Step of Its Refinancing Plan
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) reports today its business indicators for the first half of 2023 for the iCRO activity (non-audited figures) and the iBiopsy®
Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK
Regulatory News:
Sensorion (FR0012596468 – ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion Reports Positive Efficacy Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
BILENDI: Bilendi launches groundbreaking, AI-supported research platform
Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion to Host Key Opinion Leader Webinar on July 5, 2023; Confirms Upcoming Key Milestones
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Novo Nordisk beginnt exklusive Verhandlungen über den Erwerb einer Mehrheitsbeteiligung an BIOCORP, der ein Kaufangebot für alle verbleibenden Aktien folgen soll
Regulatory News:
Novo Nordisk A/S und BIOCORP Production SA (Paris:ALCOR) meldeten heute, dass Novo Nordisk exklusive Verhandlungen über eine Mehrheitsbeteiligung an BIOCORP aufgenommen hat
Novo Nordisk Enters Into Exclusive Negotiations to Acquire a Controlling Stake in BICORP, to Be Followed by a Tender Offer on All Remaining Shares.
Regulatory News:
Novo Nordisk A/S and BIOCORP Production SA (Paris:ALCOR) announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which
Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 20, 2023
Regulatory News:
The shareholders of Median Technologies (ALMDT:PA) (Paris:ALMDT) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, announces today the results of
Valbiotis meldet durchschlagenden Erfolg der internationalen multizentrischen Phase-II/III-Studie REVERSE-IT zu TOTUM•63: nachgewiesene Wirksamkeit bei Hauptrisikofaktor für Typ-2-Diabetes
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/PME-fähig) (Paris:ALVAL), ein kommerziell ausgerichtetes Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen
Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM•63: Proven Efficacy on the Main Risk Factor of Developing Type 2 Diabetes
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible) (Paris:ALVAL), a commercially oriented Research and Development company committed to scientific innovation for preventing and
Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce its participation in
MYHOTELMATCH: Strong Financial Results of MYHOTELMATCH Subsidiaries confirmed
BILENDI: Q1 2023 revenues: €13.8 million up +3%, +4.4% at constant exchange rates
Sensorion to Host a Symposium during ISIET’s International Symposium on Inner Ear Therapeutics on April 30, 2023
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, is pleased to announce it will host a
Median Technologies to Host Two Webcasts and Provide a Company Update on May 3, 2023
Regulatory News:
Median Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and Founder of Median Technologies, will provide a company update on May 3rd, 2023 during two webcasts: